Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium-difficile-infections; Inflammatory bowel diseases
- Focus Pharmacokinetics
- Acronyms PROFILE
- Sponsors Astellas Pharma Europe Ltd
- 14 Nov 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2016.